Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Maxime Kempers has a total of 24 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Histone methyltransferase DOT1L maintains cell state and restricts cytotoxic potential of CD8 T cells

    by Muddassir Malik, Willem-Jan de Leeuw, Muhammad Assad Aslam, Eliza Mari Kwesi-Maliepaard, Teun van Den Brand, Bram van Den Broek, Maxime Kempers, Liesbeth Hoekman, Natalie Proost, Tibor van Welsem, et al.

    The histone methyltransferase DOT1L is emerging as a central epigenetic regulator in immune cells. Loss of DOT1L during development of CD8 T cells in vivo leads to gain of memory characteristics but has also been reported to compromise CD8 T cell viability and antitumor reactivity. Here, we determined the cell-intrinsic role of DOT1L in mature mouse CD8 T cells. After conditional deletion of Dot1L in vitro, CD8 T cells retained in vivo proliferative capacity and antitumor reactivity. Moreover, Dot1L knockout CD8 T cells showed increased antigen-specific cytotoxicity toward tumor cells in vitro. Mechanistically, loss of DOT1L resulted in an altered cell state with loss of T cell and gain of innate-like features. These transcriptional changes were mediated by loss of DOT1L methyltransferase activity in a dose-dependent manner. Our findings show that in mature CD8 T cells, ablation of DOT1L activity is well tolerated and reprograms them to gain innate-like memory cell characteristics and enhance intrinsic cytotoxic capacity.


  • Open Access

    Histone methyltransferase DOT1L maintains identity and restricts cytotoxic potential of CD8 T cells

    by Muddassir Malik, Willem-Jan de Leeuw, Muhammad Assad Aslam, Eliza Mari Kwesi-Maliepaard, Teun van Den Brand, Bram van Den Broek, Maxime Kempers, Liesbeth Hoekman, Natalie Proost, Tibor van Welsem, et al.

    The histone methyltransferase DOT1L is emerging as a central epigenetic regulator in immune cells. Loss of DOT1L during development of CD8 T cells in vivo leads to gain of memory-features but has also been reported to compromise CD8 T cell viability and activity. Here, we determined the cell-intrinsic role of DOT1L in mature mouse CD8 T cells. After conditional deletion of Dot1L in vitro, CD8 T cells retained in vivo proliferative capacity and anti-tumor reactivity. Moreover, Dot1L knock-out CD8 T cells showed increased antigen-specific cytotoxicity towards tumor cells in vitro. Mechanistically, loss of DOT1L resulted in an altered cell-identity program with loss of T-cell and gain of NK-cell features. These transcriptional changes were mediated by loss of DOT1L methyltransferase activity in a dose-dependent manner. Our findings show that ablation of DOT1L activity in mature CD8 T cells is well-tolerated and rewires their cell identity towards the NK-cell lineage, concomitantly enhancing intrinsic cytotoxic capacity. Highlights: Differentiation and identity of cytotoxic T cells depend on the methyltransferase DOT1L DOT1L intrinsically limits the cytotoxic activity of mature CD8 T cells DOT1L prohibits the acquisition of NK cell features in CD8 T cells DOT1L maintains CD8 T cell identity through its catalytic activity in a dose-dependent manner


  • Open Access

    FUT9-Driven Programming of Colon Cancer Cells towards a Stem Cell-Like State

    by Athanasios Blanas, Anouk Zaal, Irene van der Haar Àvila, Maxime Kempers, Laura Kruijssen, Mike de Kok, Marko A. Popovic, Joost C. van der Horst, Sandra J. van Vliet

    Cancer stem cells (CSCs) are located in dedicated niches, where they remain inert to chemotherapeutic drugs and drive metastasis. Although plasticity in the CSC pool is well appreciated, the molecular mechanisms implicated in the regulation of cancer stemness are still elusive. Here, we define a fucosylation-dependent reprogramming of colon cancer cells towards a stem cell-like phenotype and function. De novo transcriptional activation of Fut9 in the murine colon adenocarcinoma cell line, MC38, followed by RNA seq-based regulon analysis, revealed major gene regulatory networks related to stemness. Lewisx, Sox2, ALDH and CD44 expression, tumorsphere formation, resistance to 5-FU treatment and in vivo tumor growth were increased in FUT9-expressing MC38 cells compared to the control cells. Likewise, human CRC cell lines highly expressing FUT9 displayed phenotypic features of CSCs, which were significantly impaired upon FUT9 knock-out. Finally, in primary CRC FUT9+ tumor cells pathways related to cancer stemness were enriched, providing a clinically meaningful annotation of the complicity of FUT9 in stemness regulation and may open new avenues for therapeutic intervention.